PentaBase ApS announced that the company has obtained additional funding corresponding to 2 million DKK. The funding will be used to increase the sales of PentaBase's platform technologies, services and diagnostic tests for detection of infectious diseases.

The founder and CEO of PentaBase, Ulf Bech Christensen, said in connection with the financing, "We are very proud to finish another round of funding in PentaBase. This funding will primarily be used to increase our sales activities of existing products and the development and protection of our patent portfolio. The funding also offers us the possibility of thinking long-term, being both an advantage for the daily operation and development as well as for our customers and investors."

"We are also extremely pleased with our new investors. They share our views on the potential of PentaBase and have declared their confidence in the management and the plans, which have been outlined." The funding comes from an anonymous Danish business angel, who previously have experienced similar challenges, to those that PentaBase currently have. "We responded to an article in the newspaper about the company, describing that PentaBase sought investment to increase sales activities. We have previously invested in equities, among other things, but the potential return from this present investment in proportion to the risks is clearly more favourable. In addition it also feels good to help ensuring the creation of something which can really be of benefit to many patients and save lives," the investor said.

"I consider PentaBase's ability to attract risk capital, especially during the current critical economic circumstances, as another strong emphasis on our solutions, technological credibility and commercial potential. We will continue to focus on raising additional capital to our many promising development projects. We shall use additional 20 million DKK for this purpose," says PentaBase's board member Hans Eibe Soerensen.

PentaBase is a biotechnology company founded in 2006. The company's primary business is research and development of diagnostic tools of infectious diseases such as influenza, avian flu and a number of airborne infectious diseases as well as of diagnosis of cancer-related diseases such as cervical cancer (HPV) and leukaemia.